11:06 Uhr
ROUNDUP: Unternehmensstimmung im Euroraum hellt sich deutlich auf

BioSig's PURE EP System to Enter Sixth Clinical Trial

Dienstag, 18.10.2016 14:35 von PR Newswire

PR Newswire

As a Class II Medical Device, BioSig's PURE EP System On Short Path to Market

SANTA MONICA, CA, Oct. 18, 2016 /PRNewswire/ - Financial Press covers BioSig, Inc. (OTCBB: BSGM), a medical device company developing the PURE EP™ System, a novel cardiac electrophysiology (EP) information system. The Company's flagship medical device product is on track to commercialization in 2017.

BioSig is preparing to enter its PURE EP™ System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system developed to assist electrophysiologists in making clinical decisions in real-time, albeit diagnostic or during an ablation procedure. 

Refined in studies at prestigious institutions such as the Texas Cardiac Arrhythmia Institute, Mayo Clinic, Mount Sinai and UCLA with data presented at world-renowned conferences, the PURE EP System has the potential to shorten procedure time and reduce the necessity for repeated procedures that are frequent with current devices. Recently, the PURE EP System was featured in an article written by researchers from the prestigious Mayo Clinic and published in The Journal of the American College of Cardiology (JACC).

Many of today's EP systems have limited dynamic range, which translates into problems in needing to amplify small signals in order to see them, which ultimately distorts resolution and saturates large signals. Electrical noise is also an issue, which makes it difficult for clinicians to differentiate real physiologic signals from noise. BioSig's PURE EP System has shown effective in helping to solve these issues.

Because the PURE EP qualifies with the FDA as a Class II medical device, extensive clinical trials are not required.  BioSig plans to file for a 510(k) marketing clearance which creates a relatively short path to commercialization, and only requires BioSig to show the device to be safe and substantially equivalent to another product on the market. BioSig intends to file its 510(k) application in the first half of 2017.

Once approved for marketing, BioSig is entering into a global market for Electrophysiology EP devices will grow at a 12.1 percent a year to $5.5 billion by 2019, making it one of the fastest growing medical device segments.

Legal Disclaimer: Financial Press Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release.

SOURCE Financial Press Media Group Inc.